For these reasons, DPP-4 inhibitors have been used as adjunctive therapy to insulin therapy in patients with T1DM, aiming to modulate both glycemic control and preserve the residual function of pancreatic β cells. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.